Phase II Trial of EOquin in High-risk Superficial Bladder Cancer

Clinical trial NCT00141531 · COMPLETED

Trial details

NCT number: NCT00141531
Sponsor: Spectrum Pharmaceuticals, Inc
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Bladder Neoplasms

Start date: 2005-07-01
Primary completion: 2009-12-01
Enrollment: 53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.